PubMed:22569271
Annnotations
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 134-158 | HP_0001402 | denotes | Hepatocellular carcinoma |
| T2 | 262-267 | HP_0002664 | denotes | tumor |
| T3 | 359-364 | HP_0002664 | denotes | tumor |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 22569271-0#76#81#gene11009 | 76-81 | gene11009 | denotes | IL-24 |
| 22569271-0#96#120#diseaseC2239176 | 96-120 | diseaseC2239176 | denotes | hepatocellular carcinoma |
| 22569271-11#86#91#gene3439 | 1764-1769 | gene3439 | denotes | IFN-α |
| 22569271-11#86#91#gene3447 | 1764-1769 | gene3447 | denotes | IFN-α |
| 22569271-11#86#91#gene3439 | 1764-1769 | gene3439 | denotes | IFN-α |
| 22569271-11#86#91#gene3447 | 1764-1769 | gene3447 | denotes | IFN-α |
| 22569271-11#146#149#diseaseC2239176 | 1824-1827 | diseaseC2239176 | denotes | HCC |
| 22569271-11#243#246#diseaseC2239176 | 1921-1924 | diseaseC2239176 | denotes | HCC |
| 22569271-6#31#36#gene6772 | 914-919 | gene6772 | denotes | STAT1 |
| 22569271-6#41#46#gene8651 | 924-929 | gene8651 | denotes | SOCS1 |
| 22569271-6#155#159#gene7422 | 1038-1042 | gene7422 | denotes | VEGF |
| 22569271-6#184#189#gene6774 | 1067-1072 | gene6774 | denotes | STAT3 |
| 22569271-6#193#196#diseaseC2239176 | 1076-1079 | diseaseC2239176 | denotes | HCC |
| 22569271-8#160#163#gene1131 | 1380-1383 | gene1131 | denotes | PBS |
| 22569271-8#160#163#gene706 | 1380-1383 | gene706 | denotes | PBS |
| 22569271-8#121#124#diseaseC2239176 | 1341-1344 | diseaseC2239176 | denotes | HCC |
| 76#81#gene1100996#120#diseaseC2239176 | 22569271-0#76#81#gene11009 | 22569271-0#96#120#diseaseC2239176 | associated_with | IL-24,hepatocellular carcinoma |
| 86#91#gene3439146#149#diseaseC2239176 | 22569271-11#86#91#gene3439 | 22569271-11#146#149#diseaseC2239176 | associated_with | IFN-α,HCC |
| 86#91#gene3439243#246#diseaseC2239176 | 22569271-11#86#91#gene3439 | 22569271-11#243#246#diseaseC2239176 | associated_with | IFN-α,HCC |
| 86#91#gene3447146#149#diseaseC2239176 | 22569271-11#86#91#gene3447 | 22569271-11#146#149#diseaseC2239176 | associated_with | IFN-α,HCC |
| 86#91#gene3447243#246#diseaseC2239176 | 22569271-11#86#91#gene3447 | 22569271-11#243#246#diseaseC2239176 | associated_with | IFN-α,HCC |
| 86#91#gene3439146#149#diseaseC2239176 | 22569271-11#86#91#gene3439 | 22569271-11#146#149#diseaseC2239176 | associated_with | IFN-α,HCC |
| 86#91#gene3439243#246#diseaseC2239176 | 22569271-11#86#91#gene3439 | 22569271-11#243#246#diseaseC2239176 | associated_with | IFN-α,HCC |
| 86#91#gene3447146#149#diseaseC2239176 | 22569271-11#86#91#gene3447 | 22569271-11#146#149#diseaseC2239176 | associated_with | IFN-α,HCC |
| 86#91#gene3447243#246#diseaseC2239176 | 22569271-11#86#91#gene3447 | 22569271-11#243#246#diseaseC2239176 | associated_with | IFN-α,HCC |
| 31#36#gene6772193#196#diseaseC2239176 | 22569271-6#31#36#gene6772 | 22569271-6#193#196#diseaseC2239176 | associated_with | STAT1,HCC |
| 41#46#gene8651193#196#diseaseC2239176 | 22569271-6#41#46#gene8651 | 22569271-6#193#196#diseaseC2239176 | associated_with | SOCS1,HCC |
| 155#159#gene7422193#196#diseaseC2239176 | 22569271-6#155#159#gene7422 | 22569271-6#193#196#diseaseC2239176 | associated_with | VEGF,HCC |
| 184#189#gene6774193#196#diseaseC2239176 | 22569271-6#184#189#gene6774 | 22569271-6#193#196#diseaseC2239176 | associated_with | STAT3,HCC |
| 160#163#gene1131121#124#diseaseC2239176 | 22569271-8#160#163#gene1131 | 22569271-8#121#124#diseaseC2239176 | associated_with | PBS,HCC |
| 160#163#gene706121#124#diseaseC2239176 | 22569271-8#160#163#gene706 | 22569271-8#121#124#diseaseC2239176 | associated_with | PBS,HCC |
DisGeNet-2017-sample
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T903 | 1764-1769 | gene:3439 | denotes | IFN-α |
| T904 | 1824-1827 | disease:C2239176 | denotes | HCC |
| T905 | 1921-1924 | disease:C2239176 | denotes | HCC |
| R1 | T903 | T904 | associated_with | IFN-α,HCC |
| R2 | T903 | T904 | associated_with | IFN-α,HCC |
| R3 | T903 | T905 | associated_with | IFN-α,HCC |
| R4 | T903 | T905 | associated_with | IFN-α,HCC |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-121 | Sentence | denotes | Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. |
| TextSentencer_T2 | 122-133 | Sentence | denotes | BACKGROUND: |
| TextSentencer_T3 | 134-241 | Sentence | denotes | Hepatocellular carcinoma (HCC) has a dismal 5-year-survival rate of 10%, so novel strategies are warranted. |
| TextSentencer_T4 | 242-400 | Sentence | denotes | IL-24 mediates anti-tumor activity reducing STAT3 expression, which suggests that interferon (IFN) alpha may augment tumor cell lysis and reduce angiogenesis. |
| TextSentencer_T5 | 401-563 | Sentence | denotes | We investigated the antitumor activity of treatment with IFN-α, with the oncolytic adenovirus SG600-IL-24, or the combination of both in HCC in vitro and in vivo. |
| TextSentencer_T6 | 564-710 | Sentence | denotes | RESULTS: RT-PCR, ELISA assay and Western-blot confirmed that the exogenous IL-24 gene was highly expressed in HCC cells infected with SG600-IL-24. |
| TextSentencer_T7 | 711-882 | Sentence | denotes | Treatment with combined IFN-α and SG600-IL-24 suppressed growth and promoted apoptosis of the HepG2, MHCC97L, and HCCLM3 cell lines compared with the normal cell line L02. |
| TextSentencer_T8 | 883-1095 | Sentence | denotes | The combined therapy increased STAT1 and SOCS1 and apoptosis, but decreased the expression of the metastatic and angiogenic proteins MMP-2, XIAP, OPN, and VEGF, which are regulated by STAT3 in HCC cells in vitro. |
| TextSentencer_T9 | 1096-1219 | Sentence | denotes | To assess the effects in vivo, the HCC cell line HCCLM3 was transplanted subcutaneously into the right flanks of nude mice. |
| TextSentencer_T10 | 1220-1406 | Sentence | denotes | Mice in the IFN-α group, the SG600-IL-24 group, or the combined therapy group had significantly suppressed growth of the HCC xenografted tumors compared to the PBS control group of mice. |
| TextSentencer_T11 | 1407-1553 | Sentence | denotes | Among the mice treated with the combination of IFN-α and SG600-IL-24, three of those eight mice had long-term survival and no evidence of a tumor. |
| TextSentencer_T12 | 1554-1664 | Sentence | denotes | These mice also had decreased expression of the metastatic and angiogenic proteins MMP-2, XIAP, OPN, and VEGF. |
| TextSentencer_T13 | 1665-1677 | Sentence | denotes | CONCLUSIONS: |
| TextSentencer_T14 | 1678-1945 | Sentence | denotes | The present study demonstrated for the first time the potential antitumor activity of IFN-α combined with the oncolytic adenovirus SG600-IL-24 in HCC both in vitro and in vivo, and suggests its further development as a potential candidate for HCC cancer gene therapy. |
| T1 | 0-121 | Sentence | denotes | Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. |
| T2 | 122-133 | Sentence | denotes | BACKGROUND: |
| T3 | 134-241 | Sentence | denotes | Hepatocellular carcinoma (HCC) has a dismal 5-year-survival rate of 10%, so novel strategies are warranted. |
| T4 | 242-400 | Sentence | denotes | IL-24 mediates anti-tumor activity reducing STAT3 expression, which suggests that interferon (IFN) alpha may augment tumor cell lysis and reduce angiogenesis. |
| T5 | 401-563 | Sentence | denotes | We investigated the antitumor activity of treatment with IFN-α, with the oncolytic adenovirus SG600-IL-24, or the combination of both in HCC in vitro and in vivo. |
| T6 | 564-710 | Sentence | denotes | RESULTS: RT-PCR, ELISA assay and Western-blot confirmed that the exogenous IL-24 gene was highly expressed in HCC cells infected with SG600-IL-24. |
| T7 | 711-882 | Sentence | denotes | Treatment with combined IFN-α and SG600-IL-24 suppressed growth and promoted apoptosis of the HepG2, MHCC97L, and HCCLM3 cell lines compared with the normal cell line L02. |
| T8 | 883-1095 | Sentence | denotes | The combined therapy increased STAT1 and SOCS1 and apoptosis, but decreased the expression of the metastatic and angiogenic proteins MMP-2, XIAP, OPN, and VEGF, which are regulated by STAT3 in HCC cells in vitro. |
| T9 | 1096-1219 | Sentence | denotes | To assess the effects in vivo, the HCC cell line HCCLM3 was transplanted subcutaneously into the right flanks of nude mice. |
| T10 | 1220-1406 | Sentence | denotes | Mice in the IFN-α group, the SG600-IL-24 group, or the combined therapy group had significantly suppressed growth of the HCC xenografted tumors compared to the PBS control group of mice. |
| T11 | 1407-1553 | Sentence | denotes | Among the mice treated with the combination of IFN-α and SG600-IL-24, three of those eight mice had long-term survival and no evidence of a tumor. |
| T12 | 1554-1664 | Sentence | denotes | These mice also had decreased expression of the metastatic and angiogenic proteins MMP-2, XIAP, OPN, and VEGF. |
| T13 | 1665-1677 | Sentence | denotes | CONCLUSIONS: |
| T14 | 1678-1945 | Sentence | denotes | The present study demonstrated for the first time the potential antitumor activity of IFN-α combined with the oncolytic adenovirus SG600-IL-24 in HCC both in vitro and in vivo, and suggests its further development as a potential candidate for HCC cancer gene therapy. |